Search
Sodium lauryl sulfate
go.drugbank.com/drugs/DB00815ApprovedIt is also used in creams and pastes to properly disperse the ingredients and as research tool in protein biochemistry. SLS also has some microbicidal activity. … SLS lowers surface tension of aqueous solutions and is used as fat emulsifier, wetting agent, and detergent in cosmetics, pharmaceuticals and toothpastes.
Categories: Compounds used in a research, industrial, or household settingLomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]
Synonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDEAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalIt undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Categories: Drugs Used in DiabetesEvening primrose oil
go.drugbank.com/drugs/DB11358ApprovedNutraceuticalIn its composition it presents some fatty acids such as [DB00132] and [DB13854]. … [L2845] By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements.[L1113] By the EMA, evening primrose oil is approved in herbal preparations.[L2851]
Mixtures: PRIM E CAPSULE, Evening Primrose Oil With Vitamin EProducts: Nn EVENING PRIMROSE OIL 1000MG (with 10%GLA), Nn EVENING PRIMROSE OIL 500MG (with 10% GLA)Dupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigationalIt was first approved by the FDA in 2017. … It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Products: Dupixent 300 mg Solution for Injection in Pre-filled Syringe, Dupixent 200mg Solution for Injection in Pre-Filled SyringeRhizopus stolonifer
go.drugbank.com/drugs/DB10814ApprovedRhizopus stolonifer extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureOlezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigationalOlezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver … [A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes.
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnAn antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidineInfluenza A virus A/Michigan/45/2015 X-275 (H1N1) hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14422ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer FertigspritzeDostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigationalA prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905] … [L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month.